Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC).
Stephane Oudard
No relevant relationships to disclose
Florence Joulain
No relevant relationships to disclose
Anna De Geer
No relevant relationships to disclose
A. Oliver Sartor
No relevant relationships to disclose